NovoMix

Selected form

Insulin Aspart

Method of action: Drugs Used In Diabets, Hypoglycemic

Treatment option: Diabetes Mellitus

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of NovoMix

NovoMix is a prescription-only medication used to help manage blood sugar levels, defined by its unique blend of fast and intermediate-acting insulin.

Quick Facts

Property	Description
Active ingredient	Insulin Aspart
Form	Suspension for Injection (Pre-filled Pen)
Pharmacological class	Antidiabetic Agent, Human Insulin Analogue
Common use	Achieving stable glycemic control
Origin	Biosynthetic (Recombinant DNA origin)

Definition and Classification

NovoMix is classified as a human insulin analogue and a hypoglycemic agent manufactured using recombinant DNA technology. It is an intermediate-acting combined with fast-acting insulin. The active component, Insulin Aspart, is structurally similar to naturally produced human insulin but is engineered for specific performance advantages. NovoMix is known as a Biphasic Insulin because it contains a fixed combination of two distinct release types of Insulin Aspart that work simultaneously to manage blood glucose levels.

Composition and Dual-Action Formulation

NovoMix is supplied as a sterile, white Suspension for Injection, typically administered subcutaneously via the NovoMix FlexPen device. This feature differentiates it from preparations requiring manual drawing and mixing. It is characterized as a premixed, fixed-ratio combination product of its active ingredient. For instance, NovoMix 30 consists of 30% soluble Insulin Aspart (which is rapid-acting) and 70% protamine-crystallized Insulin Aspart (which is intermediate-acting). This specific blend creates a dual-action profile to address both the immediate and prolonged requirements for insulin in a single application.

General Purpose: Achieving Balanced Glycemic Control

The general purpose of this medication is to help patients achieve balanced glycemic control. A typical, neutral use scenario involves managing the essential need for both mealtime and background insulin coverage simultaneously. The mechanism is driven by the dual-action components: the rapid-acting component begins working quickly to manage the rise in blood sugar immediately following a meal, while the sustained-release component ensures continuous glucose uptake between meals and overnight. This coordinated effect helps maintain blood sugar within a safe and therapeutic range throughout the day, mitigating major fluctuations.

Regulatory References

EMA EPAR for NovoMix

What side effects are possible with NovoMix?

Possible Side Effects and Safety Information

The officially documented adverse effects of NovoMix (Insulin Aspart Biphasic) are strictly categorized by government regulatory bodies based on their frequency and impact on the body's systems. This safety profile establishes that the principal and Very Common potential adverse reaction is Hypoglycaemia (low blood sugar).

Other adverse reactions are grouped by system-organ class, covering effects on metabolism, the immune system, and the skin. Reactions such as changes to fat tissue (Lipodystrophy) and localized Injection site reactions are classified as Common side effects. Less frequent reactions (Uncommon) include localized Hypersensitivity reactions, temporary Peripheral oedema (swelling), and transient changes in vision (Refraction anomalies), often seen at the start of treatment. Severe, life-threatening reactions, such as Anaphylactic reactions and Severe Hypoglycaemia (which may lead to loss of consciousness), are explicitly documented in regulatory materials.

Time- and population-related safety patterns are also noted. Effects like swelling and vision changes are typically transitory and may appear upon the initiation of therapy. Specific safety considerations apply to Older Adults and patients with Renal or Hepatic Impairment, where the potential for reduced insulin requirements necessitates careful monitoring.

Crucially, the official label defines significant high-level restrictions: NovoMix is contraindicated during an existing episode of Hypoglycaemia. Furthermore, its use is prohibited for intravenous administration or in insulin infusion pumps, as these routes are associated with severe safety consequences.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for NovoMix, a hypoglycemic agent, is strictly defined by the risk and progression of hypoglycemia (low blood glucose). The regulatory documentation mandates specific actions based on the severity of this condition.

Documented Manifestations and Severe Outcomes

Classification	Manifestation/Outcome
Mild Episode	Symptoms may include tremor, headache, sweating, nervousness, anxiety, fatigue, or difficulty in concentration.
Severe Episode	May progress to unconsciousness and/or convulsions. Severe, untreated hypoglycemia carries the risk of temporary or permanent impairment of brain function or death.

Official Emergency Actions Required

Any suspected overdose requires immediate medical attention.

Mild Episodes: Treatment is the oral administration of glucose or sugary products. Patients are officially recommended to always carry a supply of sugar-containing products.
Severe Episodes (Unconsciousness): When the patient is unconscious, the required acute treatment is the administration of glucagon (0.5 to 1 mg), typically by a trained person. After regaining consciousness, oral carbohydrates should be consumed to prevent relapse.

The progression to unconsciousness or convulsions signifies the immediate need for urgent medical intervention as explicitly stated in prescribing information.

Therapeutic Uses of NovoMix

What NovoMix Treats: Main Uses and Benefits

NovoMix is commonly used in the management of Diabetes Mellitus (both Type 1 and Type 2), applied in contexts where additional symptomatic support is needed to address high blood sugar (hyperglycemia). Its fixed-ratio formulation provides supportive relief that helps address symptom clusters that may become intense or disruptive, such as post-meal blood sugar spikes and sustained, elevated glucose levels, which helps maintain a sense of stability when symptoms are more noticeable. The medication is used for easing symptoms in patients who have diabetes and need insulin to help keep their blood glucose level controlled.

The primary symptomatic benefit is that it assists with maintaining functional stability by supporting stable glucose levels, which plays a role in managing the symptoms related to long-term metabolic dysregulation. The medication is commonly used for adults, adolescents, and children (aged 10 years and above) who require additional symptomatic assistance, especially when their diabetes is considered inadequately controlled by existing regimens.

Quick Fact: Relief for Blood Glucose Fluctuations

Symptom Domain	Relief Provided
Postprandial Hyperglycemia	Helps address groups of symptoms that may appear suddenly, such as blood sugar spikes after meals.
Basal Hyperglycemia	Supports stable glucose levels, often used when symptoms intensify between meals and overnight.
Metabolic Dysregulation	Contributes to easing the symptoms associated with long-term metabolic dysregulation.

Regulatory References

European Medicines Agency (EMA) therapeutic overview

Eligibility and Restrictions for Use

Who Can and Cannot Use NovoMix

NovoMix's official eligibility is strictly defined by regulatory authorities based on population safety and data. The medicine is approved for the treatment of Diabetes Mellitus in adults and in children and adolescents aged 10 years and above.

Eligibility Domain	Official Regulatory Status
Absolute Contraindications	Absolutely prohibited for patients with known hypersensitivity to Insulin Aspart or any excipient. Must not be administered during an acute episode of hypoglycemia (low blood sugar).
Age Restriction	Not recommended for children under 10 years of age due to limited clinical experience.
Conditional Use	Patients with renal (kidney) or hepatic (liver) impairment are eligible but require intensified blood glucose monitoring and potential dose adjustment as mandated by the label.
Reproductive Status	Use during pregnancy and lactation is generally permitted, though it requires specialized clinical monitoring and possible dose adjustment for the mother.

Regulatory documents define these strict eligibility boundaries, establishing absolute exclusions (contraindications) and setting conditional use requirements based on factors such as age, organ function, and physiological status.

What should I know about interactions with other medicines?

NovoMix's official interaction profile is defined by its core role as a hypoglycemic agent, resulting primarily in pharmacodynamic (PD) interactions with other substances. Regulatory documents contain no statements regarding clinically relevant CYP-enzyme or transporter-mediated pharmacokinetic interactions. The co-administration of certain medicinal products can formally alter the glucose-lowering outcome.

Interaction Type	Examples of Interacting Medicinal Product Categories	Official Outcome Description
PD Reinforcement	Oral Antidiabetics, ACE Inhibitors, MAO Inhibitors, Salicylates	Increases the risk of a low blood sugar outcome.
PD Counteraction	Glucocorticoids, Oral Contraceptives, Thyroid Hormones, Thiazides	Decreases the glucose-lowering effectiveness.

Specific restrictions are documented for certain combinations. Co-administration with Thiazolidinediones (TZDs) requires an official caution due to a reported risk of fluid retention and heart failure. Additionally, the label identifies Alcohol as having a complex PD effect that may either intensify or reduce the glucose-lowering outcome. A mandatory administration-timing rule is established: NovoMix must be given immediately before a meal or, when necessary, soon after the start of a meal, to align with food absorption. Furthermore, regulatory documents note that patients with renal or hepatic impairment may be at a higher risk of hypoglycemia, which affects the net PD interaction outcome.

Mechanism of Action

The mechanism of NovoMix is defined by the pharmacodynamic action of Insulin Aspart, an insulin analogue that functions as an agonist at the Insulin Receptor (IR). This receptor, found primarily on muscle, adipose, and liver cells, is the initial molecular target that regulates glucose metabolism.

Activation of the IR initiates the Phosphatidylinositol 3-kinase (PI3K) pathway, an intracellular cascade that triggers the translocation of Glucose Transporters (GLUT4) to the cell membrane. This increases the movement of glucose from the bloodstream into peripheral tissues.

Simultaneously, the signaling suppresses the liver’s gluconeogenesis and glycogenolysis, thereby inhibiting its release of new glucose. This dual modulation—enhanced peripheral uptake and reduced hepatic output—results in a net shift of glucose from the vascular space into cells.

The formulation provides a biphasic mechanism: a rapid-acting component ensures immediate IR activation to address post-meal glucose loads, and a prolonged-acting component ensures sustained IR activation for coverage of background metabolic requirements.

Dosage and Administration Information

How to Use NovoMix — Administration Guidelines

NovoMix is a suspension for subcutaneous injection that must be administered according to the specific instructions provided by the prescribing physician and outlined in the product instructions.

Administration Scope

Feature	Instruction
Route of Administration	Subcutaneous injection only (e.g., abdomen, thigh, gluteal, or deltoid region).
Dosing Schedule	Dosage is individual and must be determined and adjusted by a physician based on the patient's metabolic needs and blood glucose monitoring results.
Timing in Relation to Meals	Must be given immediately before a meal (or, when necessary, soon after a meal).

Procedural Steps

Preparation: Before each use, the pre-filled pen must be resuspended to ensure the insulin is uniformly mixed. Roll the pen horizontally between the palms at least 10 times, then invert the pen at least 10 times until the liquid is uniformly white and cloudy. If the liquid contains clumps or solid white particles, the product must not be used.

Injection: The medicine is administered via subcutaneous injection. Injection sites must be rotated within the same region (e.g., rotating injections within the abdominal area) to reduce the risk of changes to the fatty tissue under the skin. NovoMix is not intended for intravenous administration, intramuscular administration, or use in insulin infusion pumps.

Dose Adjustment and Missed Doses: Dose adjustments should only be made under medical supervision. If a dose is missed, a patient should never administer a double dose to compensate. Patients should consult their doctor for guidance regarding dose adjustments based on measured pre-meal blood glucose levels.

Recent Clinical Evidence

Research Evidence / Overview of studies for NovoMix

The clinical evaluation of NovoMix is documented through various types of research, including controlled studies and observational settings. Official research describes how this medicine, with its combination of fast- and intermediate-acting insulin aspart, was evaluated in studies examining blood glucose levels in different patient groups. The following overview details the landscape of existing evidence according to official and scientific reports.

Evidence Overview for Type 2 Diabetes Mellitus

Research exploring the use of NovoMix in adults with Type 2 Diabetes typically involves Randomized Controlled Trials (RCTs) and large-scale observational studies. These studies were conducted during research scenarios often exploring short-term symptom changes related to high blood sugar. These trials were designed to monitor key outcomes, including the blood sugar marker glycosylated hemoglobin (HbA1c), as well as blood sugar levels after fasting (FPG) and after meals (PPG).

Data from these settings show patterns related to measured changes in blood sugar markers over the duration of the study period. For instance, controlled trials describe specific patterns of change in HbA1c in studies that included comparisons to premixed human insulin. Observational data further describe real-world use and how symptoms evolved in the observed populations in non-controlled settings.

Evidence Overview for Type 1 Diabetes Mellitus

Research in Type 1 Diabetes primarily consists of short-term Comparative Randomized Controlled Trials. These studies explored short-term symptom changes in adults by monitoring outcomes related to physiological strain or stress, particularly HbA1c and PPG, along with the total daily amount of insulin needed.

The research describes patterns related to physiological measures observed in the studies, which often focused on short-term changes over periods of up to 26 weeks. These studies contribute to the broader evidence landscape by providing context on short-term changes in Type 1 Diabetes management. Compared to the evidence base for Type 2 Diabetes, the research available for Type 1 Diabetes is generally less numerous and often involved smaller sample sizes.

Evidence in Children and Adolescents

NovoMix was evaluated in studies involving adolescents and children aged 10 years and above. These studies examined the same key blood sugar outcomes, such as HbA1c, as those studied in adults. The findings describe group patterns observed in these younger populations over defined time intervals. Research describes group patterns, and findings do not determine an individual's personal outcome.

Long-Term Studies and Maintenance Follow-up

The main pivotal trials supporting the use of NovoMix often have follow-up durations that were limited, typically lasting less than one year. Evidence derived from settings with varying symptom burdens over a longer time, often from observational research, describes usage patterns that extend beyond the controlled trial periods. The long-term consistency of the measured outcomes over many years is not fully established by the existing controlled research.

Current Evidence Gaps and Limitations

The evidence landscape describes various study types but includes several documented limitations. The results apply only to the populations studied. Key limitations include that comparative evidence against certain newer insulin formulations is lacking in some areas, and sample sizes were modest in some subgroup analyses. Furthermore, the limited information for long-term outcomes in controlled settings means that certainty remains low regarding effects that extend over many years.

Frequently Asked Questions (FAQ)

Common questions about NovoMix (FAQ)

Q: What is NovoMix and how does it work?

A: NovoMix is a premixed insulin product used to treat Type 1 and Type 2 diabetes mellitus in adults, adolescents, and children aged 10 years and above. It is a suspension for injection that contains insulin aspart, a modern insulin with a rapid onset of action, and a crystalline suspension of protamine-crystallised insulin aspart, which has an intermediate duration of action. The premixed formulation ensures that both rapid-acting and intermediate-acting insulin are delivered in one injection. Insulin works by helping the body's cells take up glucose from the bloodstream, thereby lowering blood sugar levels.

Q: What is the typical dosing schedule for NovoMix?

A: The dosing of NovoMix is highly individualized and determined by a healthcare provider based on the patient's specific needs, diet, and lifestyle. It is usually injected once or twice a day immediately before or after a meal. The total daily insulin requirement often varies and may be influenced by factors such as physical activity, illness, and stress. Patients must follow the specific dosing instructions given by their doctor and never adjust the dose without medical guidance.

Q: Are there any common side effects of NovoMix?

A: The most common side effect is hypoglycaemia (low blood sugar), which may cause symptoms like sweating, feeling dizzy, headache, or confusion. Other common side effects can include:

Reactions at the injection site (pain, redness, bruising)
Lipodystrophy (changes in fat tissue at the injection site, requiring frequent site rotation)
Allergic reactions (rash, itching)
Swelling in the arms or legs (edema)

Patients should be aware of the signs of low blood sugar and know how to treat it. If any side effects are severe or persistent, contact a healthcare provider.

Q: What should I do if I miss a dose of NovoMix?

A: If a dose of NovoMix is missed, it should be corrected as soon as possible, but only if it's still near the scheduled mealtime. Do not take a double dose to make up for a forgotten one. If significant time has passed since the missed dose, or if it is close to the next scheduled dose, the patient should check their blood glucose levels and contact a healthcare provider for specific advice. Always follow the instructions provided by your doctor or nurse regarding missed doses.

Q: How should NovoMix be stored?

A: Unopened NovoMix pens or cartridges should be stored in a refrigerator (at 2 C to 8 C), away from the freezer compartment. Do not freeze NovoMix. If the insulin has been frozen, it must be discarded.

Once the pen or cartridge is in use or carried as a spare, it can be kept at room temperature (below 30 C) for up to 4 weeks (28 days). The pen should not be stored in the refrigerator once in use. Always keep the cap on the pen when not in use to protect it from light. Check the expiration date before use and discard any insulin that has expired.

How should NovoMix be stored and disposed of?

How to Store and Dispose of NovoMix® 30

The storage requirements for NovoMix® 30 differ based on whether the pen is unopened or in use.

Unopened Pens: Must be stored in a refrigerator at a temperature between 2 C and 8 C. The product must be protected from light and kept away from the refrigerator’s cooling element. Do not freeze the medicine.
In-Use Pens: Must be stored below 30 C and must not be refrigerated. Once opened, the product is stable for a maximum of 4 weeks (28 days). Keep the pen cap on to protect the medicine from light.

NovoMix® 30 must be stored out of the sight and reach of children. Disposal of unused product and used needles must follow local requirements, with needles requiring a dedicated sharps container. The product should not be discarded in household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.